SG11202003216QA - Methods for monitoring vedolizumab treatment - Google Patents
Methods for monitoring vedolizumab treatmentInfo
- Publication number
- SG11202003216QA SG11202003216QA SG11202003216QA SG11202003216QA SG11202003216QA SG 11202003216Q A SG11202003216Q A SG 11202003216QA SG 11202003216Q A SG11202003216Q A SG 11202003216QA SG 11202003216Q A SG11202003216Q A SG 11202003216QA SG 11202003216Q A SG11202003216Q A SG 11202003216QA
- Authority
- SG
- Singapore
- Prior art keywords
- monitoring
- methods
- vedolizumab treatment
- vedolizumab
- treatment
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/52—Assays involving cytokines
- G01N2333/525—Tumor necrosis factor [TNF]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/06—Gastro-intestinal diseases
- G01N2800/065—Bowel diseases, e.g. Crohn, ulcerative colitis, IBS
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762570530P | 2017-10-10 | 2017-10-10 | |
| US201762593056P | 2017-11-30 | 2017-11-30 | |
| PCT/IB2018/057827 WO2019073391A1 (en) | 2017-10-10 | 2018-10-09 | Methods for monitoring vedolizumab treatment |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202003216QA true SG11202003216QA (en) | 2020-05-28 |
Family
ID=64100687
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202003216QA SG11202003216QA (en) | 2017-10-10 | 2018-10-09 | Methods for monitoring vedolizumab treatment |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20200241006A1 (en) |
| EP (1) | EP3695229A1 (en) |
| JP (2) | JP7328960B2 (en) |
| KR (1) | KR20200069333A (en) |
| AU (1) | AU2018349287A1 (en) |
| CA (1) | CA3078779A1 (en) |
| SG (1) | SG11202003216QA (en) |
| WO (1) | WO2019073391A1 (en) |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK0615129T3 (en) | 1993-03-10 | 2000-08-07 | Cedars Sinai Medical Center | Methods for selective detection of perinuclear anti-neutrophil cytoplasmic antibody from ulcerative colitis or |
| US5830675A (en) | 1993-03-10 | 1998-11-03 | Cedars-Sinai Medical Center | Methods for selectively detecting perinuclear anti-neutrophil cytoplasmic antibody of ulcerative colitis, primary sclerosing cholangitis, or type 1 autoimmune hepatitis |
| US6218129B1 (en) | 1998-05-15 | 2001-04-17 | Prometheus Laboratories, Inc. | Inflammatory bowel disease first step assay system |
| US6406862B1 (en) | 1998-10-06 | 2002-06-18 | The United States Of America As Represented By The Secretary Of The Army | Dip-stick assay for C-reactive protein |
| US6838250B2 (en) | 2000-03-31 | 2005-01-04 | Ortho-Clinical Diagnostics, Inc. | Immunoassay for C-reactive protein |
| WO2005041896A2 (en) | 2003-11-03 | 2005-05-12 | Duke University | Methods of identifying individuals at risk of perioperative bleeding, renal dysfunction or stroke |
| WO2006012472A1 (en) | 2004-07-21 | 2006-02-02 | Qualyst, Inc. | Apparatus, kits and methods for evaluating binding interactions, for detecting and quantifying binding molecules, and for sample preparation |
| US7873479B2 (en) | 2005-12-01 | 2011-01-18 | Prometheus Laboratories Inc. | Methods of diagnosing inflammatory bowel disease |
| ES2545760T3 (en) | 2008-02-25 | 2015-09-15 | Nestec S.A. | Drug selection for breast cancer therapy using antibody matrices |
| WO2010144358A1 (en) | 2009-06-08 | 2010-12-16 | Singulex, Inc. | Highly sensitive biomarker panels |
| RU2571489C2 (en) | 2009-10-26 | 2015-12-20 | Нестек С.А. | Method of detecting anti-tnf preparations and autoantibodies |
| SG194710A1 (en) | 2011-05-10 | 2013-12-30 | Nestec Sa | Methods of disease activity profiling for personalized therapy management |
| US20140051184A1 (en) | 2012-08-15 | 2014-02-20 | Nestec S.A. | Mobility shift assays for detecting anti-tnf alpha drugs and autoantibodies thereto |
| WO2015042254A1 (en) | 2013-09-18 | 2015-03-26 | The Johns Hopkins University | Bk virus serology assessment of progressive multifocal leukoencephalopathy (pml) risk |
| WO2016088068A1 (en) | 2014-12-02 | 2016-06-09 | Nestec S.A. | Methods for establishing a vedolizumab dosing regimen to treat patients with irritable bowel disease |
| EP3237004B1 (en) | 2014-12-24 | 2024-05-08 | Takeda Pharmaceutical Company Limited | Predicting outcome of treatment with an anti-alpha4 beta7 integrin antibody |
-
2018
- 2018-10-09 WO PCT/IB2018/057827 patent/WO2019073391A1/en unknown
- 2018-10-09 KR KR1020207013313A patent/KR20200069333A/en not_active Application Discontinuation
- 2018-10-09 SG SG11202003216QA patent/SG11202003216QA/en unknown
- 2018-10-09 EP EP18796754.2A patent/EP3695229A1/en not_active Withdrawn
- 2018-10-09 US US16/755,090 patent/US20200241006A1/en active Pending
- 2018-10-09 CA CA3078779A patent/CA3078779A1/en not_active Abandoned
- 2018-10-09 JP JP2020520001A patent/JP7328960B2/en active Active
- 2018-10-09 AU AU2018349287A patent/AU2018349287A1/en active Pending
-
2023
- 2023-08-04 JP JP2023127625A patent/JP2023145731A/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2020537746A (en) | 2020-12-24 |
| JP7328960B2 (en) | 2023-08-17 |
| AU2018349287A1 (en) | 2020-05-07 |
| WO2019073391A1 (en) | 2019-04-18 |
| US20200241006A1 (en) | 2020-07-30 |
| CA3078779A1 (en) | 2019-04-18 |
| EP3695229A1 (en) | 2020-08-19 |
| KR20200069333A (en) | 2020-06-16 |
| JP2023145731A (en) | 2023-10-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL262225A (en) | Methods for monitoring and treating cancer | |
| ZA201705673B (en) | Methods for treating skin | |
| HK1243900A1 (en) | Infrasonic stethoscope for monitoring physiological processes | |
| IL269371A (en) | Treatment methods | |
| PL3090416T3 (en) | Method and system for monitoring | |
| GB201501865D0 (en) | Monitoring system and method | |
| ZA201700416B (en) | Methods for treating or preventing ophthalmological conditions | |
| IL262223A (en) | Methods for monitoring and treating cancer | |
| HK1244217A1 (en) | Methods for treating proteinopathies | |
| SG11201609169UA (en) | Filtration treatment system and filtration treatment method | |
| GB201408778D0 (en) | Monitoring system and method | |
| GB2567616B (en) | Treatment method | |
| GB201401430D0 (en) | Treatment process | |
| NO20150899A1 (en) | Condition monitoring method | |
| GB201522457D0 (en) | Monitoring apparatus | |
| GB2571601B (en) | Treatment method | |
| GB2552455B8 (en) | Blood monitoring | |
| SG11202001806TA (en) | Treatment method | |
| GB201715736D0 (en) | Hydrocarbon-emissions monitoring | |
| IL270867A (en) | Treatment method | |
| IL254336A0 (en) | Novel treatment method | |
| SG11202003216QA (en) | Methods for monitoring vedolizumab treatment | |
| GB201507391D0 (en) | Patient monitoring | |
| GB201501850D0 (en) | Monitoring system and method | |
| GB201404285D0 (en) | Monitoring system and method |